Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300...

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Drug-resistant quiescent leukemic stem cells (LSCs) and impaired natural killer (NK) cell immunity cause chronic myelogenous leukemia (CML) relapse.
• Inactivation of protein phosphatase 2A (PP2A) supports CML LSC survival and compromises NK cell antitumor activity.

Purpose of the Study:

• To investigate the role of MIR300 in CML pathogenesis and its interaction with PP2A.
• To explore MIR300's function in LSC quiescence and NK cell activity.

Main Methods:

• Investigated MIR300's function and regulation by CCND2/CDK6 and SET inhibition.
• Analyzed MIR300 expression in CML LSCs, NK cells, and progenitors under bone marrow microenvironment (BMM) influence.
• Examined the effect of BCR-ABL1 on MIR300 expression.
• Assessed the role of TUG1 long noncoding RNA in LSC apoptosis evasion.
• Evaluated the therapeutic potential of MIR300 modulation and PP2A activators in vitro and in vivo.

Main Results:

• MIR300 exhibits antiproliferative and PP2A-activating functions.
• BMM signals upregulate MIR300 in CML LSCs and NK cells, inducing quiescence and impairing immune response.
• BCR-ABL1 downregulates MIR300 in CML progenitors, preventing apoptosis.
• TUG1 upregulation by quiescent LSCs limits MIR300 function.
• MIR300 modulation and PP2A activation restore NK cell activity, inhibit BMM-induced growth arrest, and induce LSC apoptosis.

Conclusions:

• MIR300 and PP2A activity are critical for CML development.
• Targeting MIR300 and PP2A offers a promising therapeutic strategy for CML by overcoming resistance and enhancing immune response.